Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.5
Journals
Cancers
Special Issues
State of the Art and Novelties in Multidisciplinary Approach to...
share announcement

State of the Art and Novelties in Multidisciplinary Approach to Soft Tissue and Bone Sarcomas

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 July 2025 | Viewed by 2251

Special Issue Editors

Dr. Ron Batash

E-Mail Website
Guest Editor
Orthopedic Oncology Unit, Barzilai Medical Center, Affiliated to the Faculty of Medicine Ben Gurion University, Ashkelon, Israel
Interests: resection; rare tumors; cryosurgery; osteosaroma; chondrosarcoma; ewing sarcoma; limb reconstruction; reconstrucive surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Alberto Crimì

E-Mail Website
Guest Editor
Ortopedia e Oncologia Ortopedica, Azienda Ospedaliera Università di Padova, Padova, Italy
Interests: bone tumor; surgery
Prof. Dr. Moshe Schaffer

E-Mail Website
Guest Editor
Oncology Department, Barzilai Medical Center, Ashkelon, Israel
Interests: sarcoma; therapy
Prof. Dr. Pietro Ruggieri

E-Mail Website
Guest Editor
Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology and Gastroenterology DiSCOG, University of Padua, Padova, Italy
Interests: bone tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There is no current literature consensus regarding the optimal diagnostic and treatment approach to soft tissue sarcomas (STSs). Recent publications highlighted new biological aspects and deeper genetic characterization of different types of STS, up-to-date research works focused on a highly personalized medicine approach to the treatment of STS, and modern imaging techniques (e.g. PET-MRI).

In the past decade, the use of neoadjuvant and adjuvant chemotherapy, new developed immunotherapies, combined Hyperthermia with chemo-irradiation, and advances in radiation therapy techniques, like Stereotactic Body Radiation Therapy (SBRT) or the use of Artificial Intelligence to detect radio-sensitive areas of the STS, were studied but conclusive results are still debated.

The growing importance of a multidisciplinary approach of joint surgical and medical treatment of STS, involving an orthopedic surgeon, radiologist, pathologist, vascular, general, and plastic surgeon, medical oncologist, and radiation oncologist, is becoming more prominent.

The aim of the Special issue Is to provide readers with a full comprehensive data collection on up-to-date studies and treatments for defining shared guidelines and obtaining a consensus in approaches to STS.

The following types of submissions will be considered: original studies, meta-analysis and systematic reviews, clinical trial studies. 

Dr. Ron Batash
Dr. Alberto Crimì
Prof. Dr. Moshe Schaffer
Prof. Dr. Pietro Ruggieri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • soft tissue sarcoma
  • bone sarcoma
  • treatment
  • diagnosis
  • radiation therapy
  • chemotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2289 KiB  
Article
Perioperative Systemic Therapy in Rare, Chemosensitive Subtypes of Retroperitoneal Sarcoma: A Hospital-Based Propensity Score-Matched Analysis
by Benjamin Wiesler, Laleh Forountani, Amir Ashraf Ganjouei, Lara Studerus, Christoph Kettelhack, Fatime Krasniqi, Benjamin Kasenda, Beat P. Müller, Mohamed A. Adam and Alexander Wilhelm
Cancers 2025, 17(12), 1931; https://doi.org/10.3390/cancers17121931 - 10 Jun 2025
Viewed by 154
Abstract
Background: There is an ongoing debate about the role of perioperative chemotherapy in retroperitoneal sarcoma (RPS). The aim of this study was to evaluate the effectiveness of perioperative chemotherapy in subtypes of RPS that are considered chemosensitive, including retroperitoneal angiosarcoma, undifferentiated pleomorphic sarcoma, [...] Read more.
Background: There is an ongoing debate about the role of perioperative chemotherapy in retroperitoneal sarcoma (RPS). The aim of this study was to evaluate the effectiveness of perioperative chemotherapy in subtypes of RPS that are considered chemosensitive, including retroperitoneal angiosarcoma, undifferentiated pleomorphic sarcoma, myxoid liposarcoma, spindle cell sarcoma, and synovial sarcoma. Methods: This is a population-based retrospective cohort study. Patients with localized retroperitoneal sarcoma who underwent surgery were included from the US National Cancer Database (NCDB). After propensity score matching for the factors age, sex, grade, margin status, and tumor size, multivariable logistic and Cox regression analyses were used to identify factors associated with systemic therapy and their potential impact on the survival of patients with localized RPS. Results: We included 851 patients who underwent surgery between 2004 and 2020 (85% white, 41% female, and mean age 62 years). Of those, 227 patients (26.7%) received perioperative chemotherapy. In multivariable logistic regression, age ≤ 60 and tumor grading GIII/IV vs. GI/II were associated with a higher probability of receiving perioperative chemotherapy. After propensity score matching, we detected no difference in overall survival between patients who received chemotherapy and those who did not (HR 0.89, CI 0.55–1.43; and log-rank p = 0.92). Patient age ≤80 and tumor grading GI/II vs. GIII/IV were associated with improved overall survival. Conclusions: In this large analysis, the use of perioperative chemotherapy was not associated with improved survival in rare, chemosensitive subtypes of retroperitoneal sarcoma. However, selection bias must be considered when interpreting these findings. Full article
(This article belongs to the Special Issue State of the Art and Novelties in Multidisciplinary Approach to Soft Tissue and Bone Sarcomas)
►▼ Show Figures

Figure 1

15 pages, 5384 KiB  
Article
Clinical Differences Among Histological Categories of Sarcoma: Insights from 97,062 Patients
by Yiqun Han, Ahmed Shah, Yuan Yao, Robert W. Mutter and Meng Xu-Welliver
Cancers 2025, 17(10), 1706; https://doi.org/10.3390/cancers17101706 - 20 May 2025
Viewed by 372
Abstract
Objectives: To evaluate the clinical heterogeneity of sarcomas by examining associations between histological subtypes, metastatic patterns, treatment modalities, and survival outcomes. Methods: We analyzed data from 97,062 adult patients diagnosed with sarcoma between 2000 and 2020, using the Surveillance, Epidemiology, and End Results [...] Read more.
Objectives: To evaluate the clinical heterogeneity of sarcomas by examining associations between histological subtypes, metastatic patterns, treatment modalities, and survival outcomes. Methods: We analyzed data from 97,062 adult patients diagnosed with sarcoma between 2000 and 2020, using the Surveillance, Epidemiology, and End Results (SEER) database. Fourteen histological subtypes were included. Propensity score matching (PSM) was employed to adjust for baseline differences, and Cox proportional hazards models were used to identify prognostic variables. Results: The most prevalent subtypes were sarcoma not otherwise specified (31.9%), leiomyosarcoma (17.1%), and liposarcoma (13.9%). Metastatic patterns differed significantly by subtype; liver metastases were most common in sarcomas with small blue round cell (SBRC) features (8.9%) and stromal sarcoma (6.1%), while lung metastases were frequently observed in Ewing sarcoma (10.0%) and rhabdomyosarcoma (9.7%). Median overall survival (mOS) varied widely, ranging from 234 months in chondrosarcoma to 16–20 months in rhabdomyosarcoma and SBRC sarcoma. Overall, patients with primary sarcoma had significantly better survival than those with treatment-related disease (119.0 vs. 45.0 months, p < 0.0001), with this trend consistent across most subtypes. Treatment responses were subtype- and size-dependent. For instance, surgery plus radiotherapy improved outcomes in giant cell sarcoma regardless of tumor size, whereas chemotherapy provided benefit only in tumors larger than 5 cm. Combined surgery and radiotherapy offered additional survival benefit in select subtypes, including chordoma, leiomyosarcoma (>5 cm), and synovial sarcoma (<5 cm). Conclusions: Sarcomas exhibit substantial clinical and prognostic heterogeneity across histological subtypes. These findings underscore the importance of subtype-specific, individualized treatment strategies in optimizing patient outcomes. Full article
(This article belongs to the Special Issue State of the Art and Novelties in Multidisciplinary Approach to Soft Tissue and Bone Sarcomas)
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 55756 KiB  
Review
Inflammatory Myofibroblastic Tumor: An Updated Review
by Joon Hyuk Choi
Cancers 2025, 17(8), 1327; https://doi.org/10.3390/cancers17081327 - 15 Apr 2025
Cited by 1 | Viewed by 1207
Abstract
Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm that is characterized by a proliferation of myofibroblastic and fibroblastic spindle cells, accompanied by an inflammatory infiltrate that is abundant in plasma cells, lymphocytes, and eosinophils. IMT can arise in various anatomical locations but most [...] Read more.
Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm that is characterized by a proliferation of myofibroblastic and fibroblastic spindle cells, accompanied by an inflammatory infiltrate that is abundant in plasma cells, lymphocytes, and eosinophils. IMT can arise in various anatomical locations but most commonly occurs in the abdominal cavity, retroperitoneum, and lung, particularly in children and young adults. IMT typically demonstrates local invasion or recurrence, whereas metastasis is rare. IMTs pose a diagnostic challenge because of their overlapping morphological characteristics with a heterogeneous group of nonneoplastic and neoplastic lesions. Precise diagnosis is crucial for optimal management and accurate prognostication. Despite recent advancements in IMT diagnosis and treatment, its biological complexity and clinical management remain challenging due to significant histological heterogeneity and molecular genetic diversity. This review provides comprehensive updates on the clinical, molecular, and pathological characteristics of IMT, highlighting the diagnostic approaches and key differential diagnoses. Full article
(This article belongs to the Special Issue State of the Art and Novelties in Multidisciplinary Approach to Soft Tissue and Bone Sarcomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop